ConductScience.org, home
Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults
API referenceFor AI assistants

Trial · NCT05874713

Registered outcomes53

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 20 of 53

Download this page as JSON
ListOutcomeTime frameDescription
PrimaryGeometric mean titer (GMT) of hemagglutination inhibition (HI) antibodies against H5N8 strain - Day 1Day 1GMT (HI) prevaccination
PrimaryGMT of HI antibodies against H5N8 strain - Day 22Day 22GMT (HI) 3 weeks post first priming vaccination
PrimaryGMT of HI antibodies against H5N8 strain - Day 43Day 43GMT (HI) 3 weeks post second priming vaccination
PrimaryGMT of HI antibodies against H5N8 strain - Day 202Day 202GMT (HI) pre booster vaccination
PrimaryGMT of HI antibodies against H5N8 strain - Day 209Day 209GMT (HI) 1 week post booster vaccination
PrimaryGMT of HI antibodies against H5N8 strain - Day 223Day 223GMT (HI) 3 weeks post booster vaccination
PrimaryGMT of HI antibodies against H5N6 strain - Day 1Day 1GMT (HI) prevaccination
PrimaryGMT of HI antibodies against H5N6 strain - Day 22Day 22GMT (HI) 3 weeks post first priming vaccination
PrimaryGMT of HI antibodies against H5N6 strain - Day 43Day 43GMT (HI) 3 weeks post second priming vaccination
PrimaryGMT of HI antibodies against H5N6 strain - Day 202Day 202GMT (HI) pre booster vaccination
PrimaryGMT of HI antibodies against H5N6 strain - Day 223Day 223GMT (HI) 3 weeks post booster vaccination
PrimaryGeometric mean fold increase (GMFI) of HI antibodies against H5N8 strain - Day 22Day 22GMFI (HI) 3 weeks post first priming vaccination compared to prevaccination
PrimaryGMFI of HI antibodies against H5N8 strain - Day 43Day 43GMFI (HI) 3 weeks post second priming vaccination compared to prevaccination
PrimaryGMFI of HI antibodies against H5N8 strain - Day 209Day 209GMFI (HI) 1 week post booster vaccination compared to pre booster vaccination
PrimaryGMFI of HI antibodies against H5N8 strain - Day 223Day 223GMFI (HI) 3 weeks post booster vaccination compared to pre booster vaccination
PrimaryGMFI of HI antibodies against H5N6 strain - Day 22Day 22GMFI (HI) 3 weeks post first priming vaccination compared to prevaccination
PrimaryGMFI of HI antibodies against H5N6 strain - Day 43Day 43GMFI (HI) 3 weeks post second priming vaccination compared to prevaccination
PrimaryGMFI of HI antibodies against H5N6 strain - Day 223Day 223GMFI (HI) 3 weeks post booster vaccination compared to pre booster vaccination
PrimaryPercentages of subjects with HI titers ≥1:40 against H5N8 strain - Day 1Day 1% ≥1:40 (HI) prevaccination
PrimaryPercentages of subjects with HI titers ≥1:40 against H5N8 strain - Day 22Day 22% ≥1:40 (HI) 3 weeks post first priming vaccination

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05874713/registered

API referenceFor AI assistants